GLP-1 agonists may reduce heart failure risk in people diabetes and plasma cell disorder

A woman taking a GLP1-agonist. Getty/coldsnowstorm

By Olivia Bowthorpe

Glucagon-like peptide-1 (GLP-1) receptor agonists may have a “primary prevention role” in people with monoclonal gammopathy of undetermined significance (MGUS) and type 2 diabetes, a study has found.

A new international study, from the Yale School of Medicine in Connecticut, found significantly lower rates of major adverse cardiovascular and cerebrovascular events or all-cause mortality in patients with both conditions who were receiving the drugs.¹